Investigational anti-clotting drug reduces risk of second ischemic stroke without bleeding concerns

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary late-breaking science presentation at the American Stroke Association’s International Stroke Conference 2026.